


or a pharmaceutically acceptable salt thereof,
wherein:

R_1 is a bond $-H$, $-C_6H_5$, $-C_6H_4N^+$,



wherein X is a halogen and Y is an alkyl group and

wherein C_6H_5 indicates bonding to R_2 at any position
and C_6H_4 indicates bonding to R_2 and the substituent
at any position; and


R_2 is a bond, $-(CY'_2)_n$, $-(CY'_2-CY'=CY')_n$,

$-(CY'_2-CY'_2-CH=CH)_n$, $-(CY'=CY')_n$, or $-(CY'_2-\overset{O}{\parallel}{C})_n$,

wherein Y' is hydrogen or an alkyl group and wherein n
is 1 to 8; and



R_3 is $-Y''$, $-OH$, $-NH_2$, $-N^+(Y'')_3$, $-COCH_3$, $-COO^-$,
 $-SO_3H$, $-SO_3^-$, $-C-PO_3H_2$ or $-C-PO_3H^-$, wherein Y'' is an
alkyl group.


Fig. 1A





or a pharmaceutically acceptable salt thereof,

wherein:

each R_1' is independently a bond, , 




wherein Y'' is an alkyl group, and wherein  indicates bonding to R_1' at any position and  indicates bonding to R_1' and the R_1' phenyl substituent at any position;

each R_2' is independently a bond, or $-(CH_2)_n-$ wherein n is 1-4,


each R_3' is independently $-Y''$, $-Y'''$, $-H$, $-OH$, $-OY''$, $-NO_2$, $-CN$, $-NH_2$, $-COOH$, $-COY''$, $-COO^-$, or a heterocyclic group, wherein Y'' is as defined above and Y''' is a primary, secondary, tertiary or quaternary amine.

Fig. 1B.

Fig. 1C



I




II

R₁ through R₈ are, independently, -H, alkyl, 2-hydroxyalkyl, methoxyalkyl, halogen, nitro, cyano, trialkylammonium, formyl, amide of carboxylic acid, alkyl ester of carboxylic acid, carboxylic acid, glucuronyl or glyceryl ester of carboxylic acid, 1,2-dihydroxyalkyl, acetyl, vinyl, glycosyl or, taurate, and


β, γ and δ are, independently, -H, acetyl, glycyl, benzoate, phenylsulfonate, 2-, or 3-, or 4-N-alkyl-pyridyl, nitrophenyl, halophenyl, methoxyalkyl, halogen, nitro, cyano, trialkylammonium, formyl, amide of carboxylic acid.

Fig 1D



1051367 012020

Fig. 1E




I


or pharmaceutically acceptable salt thereof

wherein:

R_1 and R_2 are the same and are:




R_3 and R_4 are the same and are:



Y is halogen or $-CO_2X$,

each X is the same or different and is an alkyl and each R_5 is the same or different (preferably the same) and is H or alkyl.

Fig 1 E



or pharmaceutically acceptable salt thereof

wherein:

R_1 and R_3 are, independently:

$-\text{CO}_2\text{C}_{1-4}$ alkyl; or

$-\text{CO}_2(\text{CH}_2)_n\text{CX}_3$, wherein X is halogen and $n = 1$ to 3;

R_2 is:

-H

$-\text{C}_{1-4}$ alkyl

$-\text{COOH}$

$-\text{CO}_2\text{C}_{1-4}$ alkyl,

$-\text{CO}_2(\text{CH}_2)_n\text{CX}_3$, wherein X is halogen and $n = 1$ to 3,

$-\text{CON}(\text{CH}_3)_2$, or

$-\text{CX}_3$, wherein X is halogen; and

R_4 is:

-H,

$-\text{C}_{1-4}$ alkyl

$-\text{COOH}$,


$-\text{CO}_2\text{C}_{1-4}$ alkyl,

$-\text{CO}_2(\text{CH}_2)_n\text{CX}_3$, wherein X is halogen and $n = 1$ to 3,

$-\text{CON}(\text{CH}_3)_2$, or


$-\text{CX}_3$, wherein X is halogen.

Fig 1G



I

or



II,

or pharmaceutically acceptable salt thereof,

wherein

each R is, independently, a C₁-C₈ alkyl group,

and

each P is, independently, an electron withdrawing group or hydrogen.











Fig. 1H continued

10054367.01.0000






Figure 2A





Figure 2B



Effect of Radiation & AEOL 10113 on Mammary Adenocarcinoma




Fig 2C

Tumor Growth Inhibition
R3230 AC Mammary Adenocarcinoma in Fisher rats





Figure 4

Tumor growth inhibition (s.q. chambers)

Dose = 6 mg/kg



Tumor Angiogenesis

Dose = 6 mg/kg





Figure 6



Catalytic Antioxidant Metalloporphyrin
[MnTBAP]

10051357 012202

Figure 7




Figure 8





Figure 9

A



B






Figure 10



1051367.012202

Figure 11



bioRxiv preprint doi: <https://doi.org/10.1101/000000>; this version posted January 1, 2015. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

Figure 12




Figure 13A




Figure 13B




Figure 14





Figure 15



A549 3H-Thymidine uptake at 24 hours




Figure 17








Figure 18

INC-01 Blinded Mucositis Scores



Percentage of Study Days with Ulceration as Indicated by a Score of 3 or Greater

